About ObsEva (NASDAQ:OBSV)
ObsEva SA, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for women suffering from reproductive health and pregnancy disorders. It is developing OBE2109, an oral gonadotropin-releasing hormone receptor antagonist for the treatment of pain associated with endometriosis and heavy menstrual bleeding associated with uterine fibroids in pre-menopausal women; nolasiban, an oral oxytocin receptor antagonist to enhance clinical pregnancy and live birth rates in women undergoing in vitro fertilization; and OBE022, an oral and selective prostaglandin F2a, or PGF2a receptor antagonist, as a once daily treatment for preterm labor in weeks 24 to 34 of gestational age. The company was founded in 2012 and is headquartered in Plan-les-Ouates, Switzerland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:OBSV
CUSIPN/A
Phone41-22-552-3840
Debt
Debt-to-Equity RatioN/A
Current Ratio11.99%
Quick Ratio11.99%
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$3.30 per share
Price / Book3.95
Profitability
EPS (Most Recent Fiscal Year)($2.25)
Net Income$-66,920,000.00
Net MarginsN/A
Return on Equity-64.97%
Return on Assets-58.54%
Miscellaneous
Employees39
Outstanding Shares37,130,000
ObsEva (NASDAQ:OBSV) Frequently Asked Questions
What is ObsEva's stock symbol?
ObsEva trades on the NASDAQ under the ticker symbol "OBSV."
How were ObsEva's earnings last quarter?
ObsEva (NASDAQ:OBSV) issued its quarterly earnings data on Friday, March, 9th. The company reported ($0.48) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.56) by $0.08. View ObsEva's Earnings History.
When is ObsEva's next earnings date?
What price target have analysts set for OBSV?
5 Wall Street analysts have issued 12-month price targets for ObsEva's stock. Their forecasts range from $18.00 to $27.00. On average, they anticipate ObsEva's share price to reach $21.80 in the next twelve months. View Analyst Ratings for ObsEva.
What are Wall Street analysts saying about ObsEva stock?
Here are some recent quotes from research analysts about ObsEva stock:
- 1. According to Zacks Investment Research, "ObsEva SA is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of novel therapeutics for woman's reproductive health and pregnancy. ObsEva SA is headquartered in Geneva, Switzerland. " (3/15/2018)
- 2. HC Wainwright analysts commented, "EDELWEISS Blooming Next Quarter; Reiterate Buy Stock Data Intraday 03/09/2018 Price $14.00 Exchange NASDAQ Price Target $27.00 52-Week High $15.81 52-Week Low $5.00 Enterprise Value (M) $409.2 Market Cap (M) $520 Public Market Float (M) 13.4 Shares Outstanding (M) 37.1 3 Month Avg Volume 35,780 Short Interest (M) 0.03 Balance Sheet Metrics Cash (M) $110.8 Total Debt (M) $0.0 Total Cash/Share $2.99 Book Value/Share $2.84 EPS Diluted Full Year – Dec 2016A 2017A 2018E 1Q (0.22) (0.58) (0.45) 2Q — (0.61) (0.44) 3Q (0.30) (0.59) (0.51) 4Q (0.51) (0.48) (0.51) FY (1.40) (2.25) (1.92) 16 14 12 10 8 6 4 MAR- 17 J UL- 17 NOV- 17 MAR- 18 2 1.5 1 0.5 0 Vol. (mil) Price Financial results reported—net loss in-line with forecast. This morning, ObsEva S.A. reported its financial results for the fourth quarter and full-year 2017." (3/9/2018)
Who are some of ObsEva's key competitors?
Some companies that are related to ObsEva include Alder BioPharmaceuticals (ALDR), Assembly Biosciences (ASMB), Biohaven Pharmaceutical (BHVN), Uniqure (QURE), Mirati Therapeutics (MRTX), Amarin (AMRN), Access Pharmaceuticals (ABEO), Amphastar Pharmaceuticals (AMPH), Lexicon Pharmaceuticals (LXRX), Inflarx (IFRX), Urogen Pharma (URGN), ARMO BioSciences (ARMO), Collegium Pharmaceutical (COLL), Eagle Pharmaceuticals (EGRX), Deciphera Pharmaceuticals (DCPH), OptiNose (OPTN), Vanda Pharmaceuticals (VNDA) and GlycoMimetics (GLYC).
Who are ObsEva's key executives?
ObsEva's management team includes the folowing people:
- Dr. Ernest Loumaye, Co-Founder, CEO & Director (Age 66)
- Mr. Timothy M. Adams, Chief Financial Officer (Age 58)
- Dr. Jean-Pierre Gotteland Ph.D., Chief Scientific Officer (Age 53)
- Mr. Mario Vincent Corso, Sr. Director of Investor Relations
- Dr. Elke Bestel M.D., Chief Medical Officer and Head of Pharmacovigilance (Age 52)
When did ObsEva IPO?
(OBSV) raised $98 million in an initial public offering (IPO) on Thursday, January 26th 2017. The company issued 6,500,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Leerink Partners acted as the underwriters for the IPO.
Has ObsEva been receiving favorable news coverage?
News coverage about OBSV stock has been trending very positive recently, according to Accern. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. ObsEva earned a news impact score of 0.53 on Accern's scale. They also assigned media coverage about the company an impact score of 45.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
How do I buy shares of ObsEva?
Shares of OBSV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ObsEva's stock price today?
One share of OBSV stock can currently be purchased for approximately $13.04.
How big of a company is ObsEva?
ObsEva has a market capitalization of $495.20 million. The company earns $-66,920,000.00 in net income (profit) each year or ($2.25) on an earnings per share basis. ObsEva employs 39 workers across the globe.
How can I contact ObsEva?
ObsEva's mailing address is Chemin des Aulx 12 Plan-les-Ouates, Geneva V8, 1228. The company can be reached via phone at 41-22-552-3840 or via email at [email protected]
MarketBeat Community Rating for ObsEva (OBSV)
MarketBeat's community ratings are surveys of what our community members think about ObsEva and other stocks. Vote "Outperform" if you believe OBSV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OBSV will underperform the S&P 500 over the long term. You may vote once every thirty days.
ObsEva (NASDAQ:OBSV) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for ObsEva in the last 12 months. Their average twelve-month price target is $21.80, suggesting that the stock has a possible upside of 67.18%. The high price target for OBSV is $27.00 and the low price target for OBSV is $18.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $21.80 | $21.80 | $20.3333 | $20.40 |
| Price Target Upside: | 67.18% upside | 56.16% upside | 106.85% upside | 108.16% upside |
ObsEva (NASDAQ:OBSV) Consensus Price Target History
ObsEva (NASDAQ:OBSV) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
ObsEva (NASDAQ:OBSV) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
ObsEva (NASDAQ OBSV) Insider Trading and Institutional Ownership History
Institutional Ownership Percentage: 52.62%
ObsEva (NASDAQ OBSV) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
(Data available from 1/1/2013 forward)
ObsEva (NASDAQ OBSV) News Headlines
| Source: |
|
ObsEva (NASDAQ:OBSV) SEC Filings
This page is loading this company's SEC Filings. Please wait...
ObsEva (NASDAQ:OBSV) Income Statement, Balance Sheet and Cash Flow Statement
ObsEva (NASDAQ OBSV) Stock Chart for Thursday, April, 19, 2018
Loading chart…
